MSB 2.22% $1.10 mesoblast limited

Diabetes.......where are we at?, page-8

  1. 16,678 Posts.
    lightbulb Created with Sketch. 8125
    I suspect the issue may be, that MSB sees mileage in impressing regulators with multiple PhII trials, across multiple disease types [ie, diabetes and RA]......and aiming for lumping all that data in and saying....."can we get some type of breakthrough/early approval please".

    I'm not sure the FDA approves things on the basis of, "They are not just trying one thing; they are trying lots of things, so yeah, in that case we'll give them the green light."


    "but I think RA is just about complete with its PhII now and D is done....so a decision point has been arrived at. "

    I'm not sure what you mean by "D is done".
    Because if it was, a decision would not take so long to make.

    It's going on for 10 months since they published Phase2 trial results.

    That would be long enough a time period over which to negotiate and conclude a partnership, so they must be close to announcing one, other wise as you said, it would be a pity if they dropped the ball on this one...
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.10
Change
-0.025(2.22%)
Mkt cap ! $1.261B
Open High Low Value Volume
$1.14 $1.16 $1.09 $4.703M 4.234M

Buyers (Bids)

No. Vol. Price($)
31 338354 $1.10
 

Sellers (Offers)

Price($) Vol. No.
$1.10 56098 15
View Market Depth
Last trade - 13.29pm 29/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.